Access to Essential Medicines : Lessons Learned since the Doha Declaration on the Trips Agreement and Public Health, and Policy Options for the European Union
The study evaluates the impact of the TRIPS agreement on access to medicines in developing countries and analyses the evolving legal framework. Special emphasis is given to the issue of compulsory licensing, including recent cases in Brazil and Thailand. The EU's own implementing regulation is also presented, as well as the considerations for any TRIPS-related provisions in bilateral trade agreements of the EU and the US. The TRIPS agreement and its amendment are discussed in light of the various public health, commercial, legal and economic considerations and interests. The study also sets out conclusions and concrete recommendations to improve the overall framework of the TRIPS agreement and access to medicines.
Studie
Externí autor
Frederick M. Abbott (Florida State University, Tallahassee, Florida, U.S.A.) and Jerome H. Reichman (Duke University School of Law, Durham, North Carolina, U.S.A.)
O tomto dokumentu
Druh publikace
Klíčové slovo
- Amerika
- Asie a Oceánie
- Brazílie
- ekonomická geografie
- EKONOMIKA
- farmaceutický výrobek
- GEOGRAFIE
- hospodářská situace
- Indie
- mezinárodní obchod
- MEZINÁRODNÍ ORGANIZACE
- OBCHOD
- patentová licence
- politická geografie
- rozvojové země
- SOCIÁLNÍ OTÁZKY
- Světová obchodní organizace
- světové organizace
- Thajsko
- TRIPS
- VÝROBA, TECHNOLOGIE A VÝZKUM
- výzkum a duševní vlastnictví
- výzkum a vývoj
- zdraví
- zdraví veřejnosti